Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - risperidone 6mg;   - film coated tablet - 6 mg - active: risperidone 6mg   excipient: colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1-7000 quinoline yellow

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - nicotine polacrilex 20mg equivalent to to 4 mg nicotine;  ;   - chewing gum - 4 mg - active: nicotine polacrilex 20mg equivalent to to 4 mg nicotine     excipient: cafosa 257 classic flavour for smoker 84.6422 glycerol menthol flavour zd49284 quinoline yellow sodium carbonate sorbitol - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms thus: facilitating smoking cessation in smokers motivated to quit. helping smokers to temporarily abstain from smoking. facilitating smoking reduction in smokers unable or unwilling to quit.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate, quantity: 500 mg - capsule, hard - excipient ingredients: dimeticone 350; magnesium stearate; patent blue v; quinoline yellow; titanium dioxide; gelatin; microcrystalline cellulose; carmellose sodium; purified water; shellac; industrial methylated spirit; iron oxide black; 2-ethoxyethanol; dimeticone 1000; lecithin - indications as at 24 february 2004: keflex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of keflex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of keflex in the treatment of bacterial infections of the brain and spinal column has not been established and keflex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to keflex. renal function studies should be performed when indicated.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate, quantity: 250 mg - capsule, hard - excipient ingredients: dimeticone 350; magnesium stearate; patent blue v; quinoline yellow; titanium dioxide; gelatin; microcrystalline cellulose; carmellose sodium; purified water; shellac; industrial methylated spirit; iron oxide black; 2-ethoxyethanol; dimeticone 1000; lecithin - indications as at 24 february 2004: keflex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of keflex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of keflex in the treatment of bacterial infections of the brain and spinal column has not been established and keflex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to keflex. renal function studies should be performed when indicated.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - methyldopa sesquihydrate, quantity: 283 mg (equivalent: methyldopa, qty 250 mg) - tablet, film coated - excipient ingredients: guar gum; titanium dioxide; purified talc; sodium calcium edetate; iron oxide red; citric acid; quinoline yellow aluminium lake; hypromellose; ethylcellulose; propylene glycol; carnauba wax; magnesium stearate; powdered cellulose; colloidal anhydrous silica; citric acid monohydrate - hypertension (mild, moderate to severe).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metronidazole, quantity: 400 mg - tablet, uncoated - excipient ingredients: quinoline yellow aluminium lake; lactose monohydrate; magnesium stearate; disodium edetate; sodium starch glycollate; guar gum; colloidal anhydrous silica; ethylcellulose - metronidazole is indicated in the oral treatment of: 1. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently. 2. bacterial vaginosis. 3. all forms of amoebiasis (intestinal and extra-intestinal disease). 4. giardiasis. 5. acute ulcerative gingivitis. 6. anaerobic infections including: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative wound infections, in which the pathogens have been identified as bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronidazole may be used prophylactically to prevent infection by anaerobic organisms of the surgical site following appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and s

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - oxazepam, quantity: 30 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; quinoline yellow aluminium lake; maize starch; erythrosine aluminium lake - indications as at 25 january 2005 : alepam is indicated for: management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety associated with depression is also responsive to oxazepam therapy. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal are responsive to therapy.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - oxazepam, quantity: 15 mg - tablet, uncoated - excipient ingredients: magnesium stearate; erythrosine aluminium lake; maize starch; quinoline yellow aluminium lake; lactose monohydrate - indications as at 25 january 2005 : alepam is indicated for: management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety associated with depression is also responsive to oxazepam therapy. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal are responsive to therapy.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; acacia; magnesium stearate; quinoline yellow; calcium hydrogen phosphate dihydrate; green s - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - sulindac 100mg; sulindac 100mg - tablet - 100 mg - active: sulindac 100mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc quinoline yellow sodium starch glycolate active: sulindac 100mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc quinoline yellow sodium starch glycolate - aclin is indicated for acute or long-term use in the treatment of the following: · osteoarthritis · rheumatoid arthritis · ankylosing spondylitis · periarticular diseases such as acute painful shoulder (acute subacromial bursitis/supraspinatus tendonitis) and tenosynovitis · acute gouty arthritis · painful low back syndrome (low back pain, commonly referred to as lumbago).